Patent details

LUC00295 Product Name: Lasmiditan et ses dérivés pharmaceutiquement acceptables (RAYVOW)

Basic Information

Publication number:
LUC00295
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP107594913
Legal Status:
Inactive
Application number:
LUC00295
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/21/1587
Marketing Authorization Type:
Marketing Authorization Date:
19/08/2022
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
13/01/2023
First Marketing Authorization date:
19/08/2022
Grant date:
22/09/2025
Activation date:
Publication date:
13/01/2023
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
02/04/2035
SPC Extension Expiration:
02/04/2035
Rejection date:
Withdrawal date:

Owner

From:
13/01/2023
 
 

Name:
Colucid Pharmaceuticals, Inc.
Address:
2530 Meridian Parkway, Suite 300, Durham, NC 27713, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
13/01/2023
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2023/02
Publication date:
08/02/2023
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2025/11
Publication date:
02/10/2025
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
30/04/2030
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
13/01/2023 Marketing authorization 3
13/01/2023 Application Form 3
13/01/2023 Summary of the product caracteristics 36
13/01/2023 MA publication 8
13/01/2023 Outgoing Correspondence 1
13/01/2023 Publication 1
22/09/2025 Publication 1
22/09/2025 Certificate 1
22/09/2025 Outgoing Correspondence 1